Cargando…

Oncolytic adenovirus improves anti-tumor efficacy of adoptive T cell therapy by breaking tumor-induced immunosuppression and peripheral tolerance

Detalles Bibliográficos
Autores principales:	Tähtinen, Siri, Grönberg-Vähä-Koskela, Susanna, Lumen, Dave, Merisalo-Soikkeli, Maiju, Siurala, Mikko, Airaksinen, Anu J, Vähä-Koskela, Markus, Hemminki, Akseli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649355/ http://dx.doi.org/10.1186/2051-1426-3-S2-P315

Ejemplares similares

Favorable Alteration of Tumor Microenvironment by Immunomodulatory Cytokines for Efficient T-Cell Therapy in Solid Tumors
por: Tähtinen, Siri, et al.
Publicado: (2015)

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy
por: Havunen, Riikka, et al.
Publicado: (2016)

Oncolytic adenoviruses: A potent form of tumor immunovirotherapy
por: Cerullo, Vincenzo, et al.
Publicado: (2012)

Improving adoptive T cell therapy with adenoviruse armed with TNF-α and IL-2
por: Havunen, Riikka, et al.
Publicado: (2015)

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
por: Havunen, Riikka, et al.
Publicado: (2018)

Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy
por: Vähä-Koskela, Markus, et al.
Publicado: (2015)

Tumor Restrictions to Oncolytic Virus
por: Vähä-Koskela, Markus, et al.
Publicado: (2014)

MicroRNA-Mediated Suppression of Oncolytic Adenovirus Replication in Human Liver
por: Ylösmäki, Erkko, et al.
Publicado: (2013)

Effective Combination Immunotherapy with Oncolytic Adenovirus and Anti-PD-1 for Treatment of Human and Murine Ovarian Cancers
por: Heiniö, Camilla, et al.
Publicado: (2022)

Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1
por: Quixabeira, Dafne C. A., et al.
Publicado: (2022)

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
por: Liikanen, Ilkka, et al.
Publicado: (2015)

Local delivery of interleukin 7 with an oncolytic adenovirus activates tumor-infiltrating lymphocytes and causes tumor regression
por: Kudling, Tatiana V., et al.
Publicado: (2022)

Comparison of Clinically Relevant Oncolytic Virus Platforms for Enhancing T Cell Therapy of Solid Tumors
por: Cervera-Carrascon, Victor, et al.
Publicado: (2020)

Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors
por: Basnet, Saru, et al.
Publicado: (2022)

Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
por: Santos, João Manuel, et al.
Publicado: (2020)

Oncolytic viruses in cancer therapy
por: Vähä-Koskela, Markus J.V., et al.
Publicado: (2007)

Oncolytic adenovirus decreases the proportion of TIM-3(+) subset of tumor-infiltrating CD8(+) T cells with correlation to improved survival in patients with cancer
por: Liikanen, Ilkka, et al.
Publicado: (2022)

Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine
por: Quixabeira, D. C. A., et al.
Publicado: (2023)

Expression of DAI by an oncolytic vaccinia virus boosts the immunogenicity of the virus and enhances antitumor immunity
por: Hirvinen, Mari, et al.
Publicado: (2016)

An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage
por: Pakola, Santeri, et al.
Publicado: (2023)

Safety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory Beagles
por: Autio, Karoliina, et al.
Publicado: (2014)

Oncolytic adenovirus for treatment of malignant ascites
por: Hemminki, Akseli, et al.
Publicado: (2022)

SPECT/CT Imaging of hNIS -Expression after Intravenous Delivery of an Oncolytic Adenovirus and (131)I
por: Rajecki, Maria, et al.
Publicado: (2012)

Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition
por: Cervera-Carrascon, Victor, et al.
Publicado: (2020)

Cytokine-Coding Oncolytic Adenovirus TILT-123 Is Safe, Selective, and Effective as a Single Agent and in Combination with Immune Checkpoint Inhibitor Anti-PD-1
por: Havunen, Riikka, et al.
Publicado: (2021)

Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers
por: Santos, Joao, et al.
Publicado: (2021)

Incomplete but Infectious Vaccinia Virions Are Produced in the Absence of Oncolysis in Feline SCCF1 Cells
por: Parviainen, Suvi, et al.
Publicado: (2015)

Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus
por: Callegari, Elisa, et al.
Publicado: (2013)

Analysis of predictive and prognostic factors in 290 patients treated with oncolytic adenoviruses
por: Taipale, Kristian, et al.
Publicado: (2015)

Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy
por: Farzad, Lisa, et al.
Publicado: (2014)

Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles
por: Autio, Karoliina P. M., et al.
Publicado: (2015)

Systemic Therapy for Cervical Cancer with Potentially Regulatable Oncolytic Adenoviruses
por: Kanerva, Anna, et al.
Publicado: (2008)

Interleukin 8 activity influences the efficacy of adenoviral oncolytic immunotherapy in cancer patients
por: Taipale, Kristian, et al.
Publicado: (2018)

Using BERT to identify drug-target interactions from whole PubMed
por: Aldahdooh, Jehad, et al.
Publicado: (2022)

Oncolytic Immunotherapy: Where Are We Clinically?
por: Hemminki, Akseli
Publicado: (2014)

Ad5/3 is able to avoid neutralization by binding to erythrocytes and lymphocytes
por: Zafar, Sadia, et al.
Publicado: (2020)

Oncolytic Adenovirus Coding for a Variant Interleukin 2 (vIL-2) Cytokine Re-Programs the Tumor Microenvironment and Confers Enhanced Tumor Control
por: Quixabeira, Dafne C. A., et al.
Publicado: (2021)

Oncolytic viruses for cancer immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2020)

Defects in Innate Immunity Render Breast Cancer Initiating Cells Permissive to Oncolytic Adenovirus
por: Ahtiainen, Laura, et al.
Publicado: (2010)

TNFa and IL2 Encoding Oncolytic Adenovirus Activates Pathogen and Danger-Associated Immunological Signaling
por: Heiniö, Camilla, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_itldtnbd2fbt7sj58oa40k0gq0